NCT02319460View on ClinicalTrials.gov

An Observational Cohort Study to Investigate the Risk of Thromboembolic Events in Patients Receiving Kcentra® or Plasma to Reverse Vitamin K Antagonist (VKA) Therapy in the Setting of Acute Major Bleeding

CompletedOBSERVATIONAL

Enrollment

2,238

Participants

Timeline

Start Date

April 24, 2014

Primary Completion Date

June 30, 2020

Study Completion Date

June 30, 2020

Conditions

Hemorrhage

Interventions

BIOLOGICAL

Kcentra®

Kcentra®, Prothrombin Complex Concentrate (Human), is a blood coagulation factor replacement product that contains coagulation Factors II, VII, IX and X, and antithrombotic Proteins C and S as a lyophilized concentrate.

BIOLOGICAL

Plasma

Trial Locations (1)

94612

Study Site, Oakland